When should an antinuclear antibody (ANA) test with reflex to an extractable nuclear antigen (ENA) panel be ordered, and how are the results interpreted?

ANA with Reflex Testing: When to Order and How to Interpret

Order ANA testing only when there is well-founded clinical suspicion of an ANA-associated rheumatic disease (AARD), not as a screening test for nonspecific symptoms like isolated fatigue or undifferentiated pain. 12

When to Order ANA Testing

Clinical Indications for Testing

Order ANA when patients present with specific clinical features suggesting systemic autoimmune rheumatic disease:

• Multi-system involvement suggesting SLE (malar rash, photosensitivity, serositis, renal disease, cytopenias, neurologic manifestations)
• Raynaud's phenomenon with digital ulcers or skin thickening (systemic sclerosis)
• Inflammatory arthritis with sicca symptoms (Sjögren's syndrome)
• Proximal muscle weakness with elevated creatine kinase (inflammatory myopathies)
• Unexplained interstitial lung disease in younger patients
• Congenital heart block or neonatal lupus evaluation

12

Do NOT Order ANA For:

• Isolated fatigue without other systemic features
• Single joint pain
• Nonspecific musculoskeletal complaints
• General screening in asymptomatic individuals
• Disease activity monitoring (serial ANA testing is not appropriate)

2

Critical Caveat: Up to 25% of healthy individuals can be ANA-positive depending on the cut-off used, and the positive predictive value for SLE in a rheumatology referral cohort is only 2.1% 12. The background prevalence of ANA positivity in the general population ranges from 13-33% 2.

Understanding the Reflex Testing Strategy

The Stepwise Approach (Recommended)

When ANA is positive, reflex testing to ENA panel should be performed based on the titer, pattern, and clinical context 11. This stepwise strategy is more cost-effective than upfront parallel testing 34.

The reflex algorithm works as follows:

1. Initial ANA by IIFA (indirect immunofluorescence on HEp-2 cells - the reference standard) 1
2. If positive: Document titer and pattern
3. Reflex to specific antibodies based on pattern and clinical suspicion:
   • Homogeneous pattern → consider anti-dsDNA, anti-histone (SLE, drug-induced lupus)
   • Speckled pattern → ENA panel (anti-Sm, anti-RNP, anti-SSA/Ro, anti-SSB/La)
   • Centromere pattern → anti-centromere antibodies (limited systemic sclerosis)
   • Nucleolar pattern → anti-Scl-70, anti-RNA polymerase III (systemic sclerosis)

11

Important Exception to the Stepwise Rule

In cases of high clinical suspicion, specific antibody testing should be ordered regardless of ANA result 11. This is critical because certain antibodies can be positive despite negative ANA-IIFA:

• Anti-Jo-1 in suspected inflammatory myopathy
• Anti-SSA/Ro in Sjögren's syndrome, subacute cutaneous lupus, congenital heart block
• Anti-ribosomal P in SLE with neuropsychiatric features

11

Recent meta-analysis confirms that 14.1% of ANA-negative patients can have positive ENA, rising to 44.1% in patients with confirmed connective tissue disease 5. However, in unselected populations with negative ANA, only 6% of positive ENA results lead to new AARD diagnoses 6.

Interpreting Results

ANA-Positive Results

A positive ANA alone does not establish diagnosis - clinical context is paramount 12. Interpretation requires integration of:

1. Titer: Higher titers (≥1:160) are more clinically significant
2. Pattern: Guides differential diagnosis (see table above)
3. Clinical manifestations: Must correlate with disease features
4. Specific antibodies: Provide disease specificity

11

The Problem of Discordant Results

When ANA is negative but clinical suspicion remains high, specific antibody testing is justified 11. This addresses the 0.37% rate of clinically relevant positive ENA in ANA-negative patients with actual AARD 4.

The most common antibodies causing ANA/ENA discordance are:

• Anti-Ro52 (19.9%)
• Anti-DFS70 (17.3% - typically not disease-associated)
• Anti-Jo-1 (15.6%)

7

Reporting Requirements

Laboratories should report 11:

• Method used (IIFA vs. alternative platforms)
• Titer (quantitative or semi-quantitative)
• Pattern (for IIFA)
• Specific antibody results separately (including negative results)

Cost and Efficiency Considerations

Simultaneous ANA and ENA ordering without a structured reflex strategy is wasteful and clinically inappropriate 384. Studies demonstrate:

• Simultaneous testing occurs in 8.3-24.2% of cases inappropriately 4
• Implementation of reflex testing reduced unnecessary ENA requests from 58.44% to 20%, saving €121,000 annually in one center 8
• Upfront parallel testing requires 657 additional tests per 514 patients with minimal clinical yield (+1.4%) 3

Practical Algorithm

For suspected AARD:

1. Assess pretest probability based on specific clinical features (not nonspecific symptoms)
2. If high suspicion → Order ANA-IIFA
3. If ANA positive → Automatic reflex to pattern-appropriate specific antibodies
4. If ANA negative BUT very high clinical suspicion for specific diseases (Sjögren's, myositis, subacute cutaneous lupus) → Order disease-specific antibodies directly
5. Interpret all results in clinical context - positive serology without clinical features does not equal disease

Never order serial ANA tests for disease monitoring - use disease-specific markers like anti-dsDNA quantitatively for SLE activity instead 1.